Payam Nahid, MD, MPH

Director, UCSF Center for Tuberculosis
Co-Director, UC TRAC
Professor
Medicine
[email protected]
+1 628 206-5464

Dr. Nahid is Professor of Medicine in the Division of Pulmonary and Critical Care Medicine. His research includes the conduct of clinical trials and translational research in TB with the goal of improving the care of patients with TB and HIV/TB worldwide.  Dr. Nahid’s research focuses on clinical trials, epidemiological and translational TB research in international settings. He is leads a Vietnam National Tuberculosis Programme-partnered Clinical Trials Unit (CTU) in Hanoi, Vietnam. He is protocol co-chair of a Phase 3 clinical trial of a rifapentine-based short-course treatment regimen for active tuberculosis (TBTC Study 31 / ACTG A5349), conducted across 13 countries, with top-line results shared in Q4 2020. Dr. Nahid leads NIAID-funded TB biomarker-focused RO1’s focused on biomarker and pharmacodynamic marker for clinical trial applications. Dr. Nahid has chaired the WHO Task Force on New Drugs and Regimens for TB, and served as a member of the WHO Task Force on Global TB Research Strategy. Dr. Nahid has led US CDC Treatment of Tuberculosis guidelines and served on WHO Guideline Development Committees and as consultant on Technical Reports on TB therapeutics and vaccines.

UCSF Center for Tuberculosis Leadership & Initiatives:
UCSF Center for Tuberculosis Director
UC TRAC Co-Director
TB RAMP Co-Director
SMART4TB UCSF Project Lead
World TB Day Oversight Planning Committee Member

Featured Publications: 

Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

American journal of respiratory and critical care medicine

Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL, Dalton TL, Duarte R, Fregonese F, Horsburgh CR, Ahmad Khan F, Kheir F, Lan Z, Lardizabal A, Lauzardo M, Mangan JM, Marks SM, McKenna L, Menzies D, Mitnick CD, Nilsen DM, Parvez F, Peloquin CA, Raftery A, Schaaf HS, Shah NS, Starke JR, Wilson JW, Wortham JM, Chorba T, Seaworth B

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A

High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.

Contemporary clinical trials

Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, Heilig CM, Johnson JL, Lessem E, Metchock B, Miro JM, Nhung NV, Pettit AC, Phillips PPJ, Podany AT, Purfield AE, Robergeau K, Samaneka W, Scott NA, Sizemore E, Vernon A, Weiner M, Swindells S, Chaisson RE

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.

Nature medicine

Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM

Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.

The Lancet. Respiratory medicine

Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, Brust JCM, Campbell JR, Chang VWL, Falzon D, Guglielmetti L, Isaakidis P, Kempker RR, Kipiani M, Kuksa L, Lange C, Laniado-Laborín R, Nahid P, Rodrigues D, Singla R, Udwadia ZF, Menzies D

Identification of Mycobacterium tuberculosis Peptides in Serum Extracellular Vesicles from Persons with Latent Tuberculosis Infection.

Journal of clinical microbiology

Mehaffy C, Kruh-Garcia NA, Graham B, Jarlsberg LG, Willyerd CE, Borisov A, Sterling TR, Nahid P, Dobos KM

Sensitive electrochemiluminescence (ECL) immunoassays for detecting lipoarabinomannan (LAM) and ESAT-6 in urine and serum from tuberculosis patients.

PloS one

Broger T, Tsionksy M, Mathew A, Lowary TL, Pinter A, Plisova T, Bartlett D, Barbero S, Denkinger CM, Moreau E, Katsuragi K, Kawasaki M, Nahid P, Sigal GB

Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.

PLoS medicine

Phillips PPJ, Mitnick CD, Neaton JD, Nahid P, Lienhardt C, Nunn AJ

A Novel Sensitive Immunoassay Targeting the 5-Methylthio-d-Xylofuranose-Lipoarabinomannan Epitope Meets the WHO's Performance Target for Tuberculosis Diagnosis.

Journal of clinical microbiology

Sigal GB, Pinter A, Lowary TL, Kawasaki M, Li A, Mathew A, Tsionsky M, Zheng RB, Plisova T, Shen K, Katsuragi K, Choudhary A, Honnen WJ, Nahid P, Denkinger CM, Broger T

Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis.

Tuberculosis (Edinburgh, Scotland)

Kedia K, Wendler JP, Baker ES, Burnum-Johnson KE, Jarsberg LG, Stratton KG, Wright AT, Piehowski PD, Gritsenko MA, Lewinsohn DM, Sigal GB, Weiner MH, Smith RD, Jacobs JM, Nahid P

Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial.

EBioMedicine

Sigal GB, Segal MR, Mathew A, Jarlsberg L, Wang M, Barbero S, Small N, Haynesworth K, Davis JL, Weiner M, Whitworth WC, Jacobs J, Schorey J, Lewinsohn DM, Nahid P

Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.

Clinical pharmacology and therapeutics

Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE, Dorman SE

Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.

PLoS medicine

Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, Churchyard GJ, Nahid P, Rich ML, Bansbach C, Forissier T, Lienhardt C, Dowdy DW

Adaptation of Mycobacterium tuberculosis to Impaired Host Immunity in HIV-Infected Patients.

The Journal of infectious diseases

Walter ND, de Jong BC, Garcia BJ, Dolganov GM, Worodria W, Byanyima P, Musisi E, Huang L, Chan ED, Van TT, Antonio M, Ayorinde A, Kato-Maeda M, Nahid P, Leung AM, Yen A, Fingerlin TE, Kechris K, Strong M, Voskuil MI, Davis JL, Schoolnik GK

Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis.

The Journal of infectious diseases

Walter ND, Dolganov GM, Garcia BJ, Worodria W, Andama A, Musisi E, Ayakaka I, Van TT, Voskuil MI, de Jong BC, Davidson RM, Fingerlin TE, Kechris K, Palmer C, Nahid P, Daley CL, Geraci M, Huang L, Cattamanchi A, Strong M, Schoolnik GK, Davis JL

Reaching the limits of tuberculosis prevention among foreign-born individuals: a tuberculosis-control program perspective.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Walter ND, Jasmer RM, Grinsdale J, Kawamura LM, Hopewell PC, Nahid P